Canada’s drug regulator has issued a final positive recommendation supporting public reimbursement of Leqembi® (lecanemab) for early Alzheimer’s disease, marking a significant policy shift.
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease
